Herpes Simplex Articles & Analysis
11 articles found
Viruses commonly employed range from Herpes Simplex Viruses (HSVs), Coxsackieviruses, Reoviruses to the Vaccinia virus, chosen primarily for their proclivity to target specific types of cancer cells, and their unique ability to engender an immune response. ...
This is a replication-defective, non-integrated herpes simplex virus type 1 (HSV-1)-derived vector engineered to deliver functional full-length human CFTR to CF patients' airways via nebulization. ...
The main types of viral vectors used clinically for in vivo gene therapy include adenovirus, adeno-associated virus (AAV), herpes simplex virus (HSV), retroviruses, and lentiviruses. In recent years, scientific advances in viral vector engineering, rare disease genome identification, and gene editing are ushering in a new era of viral gene therapy. ...
Results will inform protocol design of Phase 1/2 clinical trial of Company's lead HSV-2 therapeutic vaccine candidate WOBURN, Mass. and OXFORD, England, Aug. 15, 2022 /PRNewswire/ -- Rational Vaccines, a company focused on revolutionizing the treatment and prevention of herpes to eradicate the disease, today announced the launch of a clinical trial designed to determine the ...
Rational Vaccines' experimental vaccine candidate for herpes simplex virus type 2 (HSV-2), the primary cause of genital herpes, is showing promise in preclinical studies. ...
RVx201 Herpes Vaccine Description 2022 RVx201 is a first-in-human herpes simplex virus type 2 (HSV-2) live-attenuated therapeutic vaccine modified to be interferon sensitive that destroys the ability of the virus to inhibit immune responses. ...
Approximately 500 million people worldwide suffer from genital herpes. Several billion more have an oral herpes infection. Herpes is a life-altering disease that can lead to chronic pain, blindness, and death, particularly in neonatal and pediatric populations – and a major regulator is finally paying attention and developing a vaccine for ...
Abstract Herpes simplex virus type-1 (HSV-1) can cause severe ocular infection and blindness. We have previously shown that the HSV-1 VC2 vaccine strain is protective in mice and guinea pigs against genital herpes infection following vaginal challenge with HSV-1 or HSV-2. In this study, we evaluated the efficacy of VC2 intramuscular vaccination ...
Abstract Background Although herpes simplex viruses (HSV) are a major target for vaccine development no vaccine is currently licensed. Methods A live attenuated HSV virus vaccine, VC2 was compared to a subunit HSV vaccine, glycoprotein D (gD2) administered with the adjuvant, MPL/Alum using the guinea pig model of genital herpes. Three doses of ...
Here, we tested a prophylactic live-attenuated vaccine against herpes simplex virus type 1 (HSV-1), a widespread human pathogen that can cause corneal blindness. ...
Her diagnosis? Herpes simplex virus. The World Health Organization estimates that more than 420 billion people worldwide have herpes simplex virus, commonly referred to as ...